Subscribe

Lepu Biopharma Co., Ltd. (2157.HK)

HKD4.89 +0.23 (+4.94%)
CN HKSE Healthcare Biotechnology
Address Building 41 201612
Shanghai, CN
CEO Zhongjie Pu
Website lepubiopharma.com
IPO 2022-02-23
ISIN CNE100004SM4

Explore sections of this company profile

Description

Lepu Biopharma Co., Ltd. operates as a biopharmaceutical enterprise, concentrating its efforts on the development of innovative oncology therapies. It maintains a broad pipeline of cancer-fighting products primarily aimed at the Chinese market. The company's therapeutic candidates encompass a range of modalities, including cutting-edge antibody-drug conjugates (ADCs), oncolytic virus treatments, and diverse immunotherapies. Among its immuno-oncology offerings are HX008 (an anti-PD-1 mAb) and LP002 (an anti-PD-L1 mAb). The ADC portfolio features MRG003 (targeting EGFR), MRG002 (targeting HER2), MRG001 (targeting CD20), MRG004A (targeting TF), and CMG901 (targeting CLDN18.2). Additionally, Lepu Biopharma is advancing the oncolytic virus CG0070, along with various combination therapies such as HX008+OH2, LP002+OH2, and HX008+LP002. Founded in 2018, the company is headquartered in Shanghai, China.

Market Cap & Enterprise Value
Merger & Acquisition History

No mergers or acquisitions recorded for this company.

Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary Loading…
Indicator 1D1W2W3W1M
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
Averages
Trend
Price
Levels
Draw
HKD4.89 +0.23 (+4.94%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
10M
Beta
-0.44
Float Shares
931.85M
Free Float %
51.6%
Price Performance
1D5D1M3M6M YTD1Y3Y5Y10YMax
+4.41% -7.19% -17.76% -5.75% -25.13% -14.29% -8.19% -25.91% -40.34% -40.34% -40.34%
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
vs.
Loading histogram data…

Revenue flow

Revenue by geography

Revenue by segment

From To

Revenue composition

From To

By product

By geography

Financial Statements

Income Statement

Balance Sheet

Cash Flow Statement

Key Metrics

Financial Ratios

Employees

Financial Growth (CAGR)

Market Data

Price Targets & DCF
Current price
4.89
DCF (Unlevered) 20.02 +309.4%

DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.

Ratings Trend (MoM) 100% Bullish
Rating 2026-05 Change
Strong Buy 0 0
Buy 1 0
Hold 0 0
Sell 0 0
Strong Sell 0 0
Quality scores
Altman Z-Score
1.24
Distress
Piotroski F-Score
3 / 9
Average
MOAT Score
0 / 10
No MOAT
Composite Rating
B-
Overall Score
2 / 5
Medium
DCF Score
1 / 5
Low
ROE Score
5 / 5
High
ROA Score
5 / 5
High
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
  • ✓
    Revenue growth Biotechnology: +1.6%
    +147.6% ★ Q4'25: +544.0% (vs Q4'23)
  • ✓
    EPS growth Biotechnology: +29.7%
    +158.3% ★ Q4'25: +66.7% (vs Q4'23)
  • ✓
    FCF margin FCF growth · Biotechnology: +16.2%
    +1.5% Q4'25: -18.3% (vs Q4'23)
  • ✗
    EBIT margin Biotechnology: +0.0%
    +9.6% ★ Q4'25: +1.4% (vs Q4'23)
  • ✗
    ROIC Biotechnology: -16.1%
    +5.9% ★ Q4'25: +1.8% (vs Q4'23)
  • ✗
    Share dilution Biotechnology: -3.4%
    +3.8% Q4'25: +8.8% (vs Q4'23)
  • ✗
    Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×
    5.92× Q4'25: 5.05× (vs Q4'23)
Valuation Multiples From To
Price Forecast (3Y) From To
Model
Adjust
P/E
Theoretical Return — If Invested Today

* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.

DCF Interactive Model (UFCF)
Projection years:
Market assumptions
▶ WACC components (optional)
Ke (Cost of Equity) = Rf + β (-0.41) × ERP
WACC = 86% × Ke + 14% × Kd (4.1%) × (1−t)

Modifying these values recalculates WACC automatically.

Business assumptions
—
Intrinsic value (base): 20.22 Current price: 4.89
Enterprise Value: — Equity Value: — Terminal Value: — TV as % of EV: —

Base values reflect the latest available data for this company and market conditions.

Consensus Estimates
Metric Dec 2022
actual 		Dec 2023
actual 		Dec 2024
actual 		Dec 2025
actual 		Dec 2026
1 Rev. Ana.
1 EPS Ana. 		Dec 2027
1 Rev. Ana.
1 EPS Ana. 		Dec 2028
1 Rev. Ana.
1 EPS Ana.
Revenue
15.57M
est: 52.41M (-70.3%)
225.35M
est: 190.77M (+18.1%)
367.79M
est: 279.65M (+31.5%)
910.67M
est: 852.65M (+6.8%)
1.11B
1.11B – 1.11B
+30.1% YoY
1.59B
1.59B – 1.59B
+42.9% YoY
2.34B
2.34B – 2.34B
+47.3% YoY
EBITDA
-596.53M
est: 5.64M (-10,683.6%)
86.95M
est: -10.15M (+956.6%)
-311.94M
est: -14.88M (-1,996.4%)
178.73M
est: -45.37M (+494.0%)
-59.05M
-59.05M – -59.05M
-30.1% YoY
-84.40M
-84.40M – -84.40M
-42.9% YoY
-124.28M
-124.28M – -124.28M
-47.3% YoY
EBIT
-691.97M
est: -726.8K (-95,112.5%)
-15.62M
est: -37.14M (+57.9%)
-395.85M
est: -54.44M (-627.2%)
87.43M
est: -165.98M (+152.7%)
-216.02M
-216.02M – -216.02M
-30.1% YoY
-308.77M
-308.77M – -308.77M
-42.9% YoY
-454.67M
-454.67M – -454.67M
-47.3% YoY
Net Income
-689.05M
est: -772.97M (+10.9%)
-22.10M
-411.38M
est: -280.71M (-46.5%)
254.60M
est: -17.54M (+1,551.2%)
72.88M
72.88M – 72.88M
+515.4% YoY
273.28M
273.28M – 273.28M
+275.0% YoY
564.79M
564.79M – 564.79M
+106.7% YoY
SGA
140.58M
est: 128.42M (+9.5%)
129.95M
est: 442.22M (-70.6%)
237.89M
est: 648.26M (-63.3%)
309.10M
est: 1.98B (-84.4%)
2.57B
2.57B – 2.57B
+30.1% YoY
3.68B
3.68B – 3.68B
+42.9% YoY
5.41B
5.41B – 5.41B
+47.3% YoY
EPS
-0.42
est: -0.46 (+8.1%)
-0.01
-0.24
est: -0.16 (-50.1%)
0.14
est: -0.01 (+1,500.6%)
0.04
0.04 – 0.04
+515.4% YoY
0.16
0.16 – 0.16
+275.0% YoY
0.32
0.32 – 0.32
+106.7% YoY
Historical Ratings (3M)
Date Rating Overall DCF ROE ROA D/E P/E P/B
2026-05-29 B- 2/5 1/5 5/5 5/5 1/5 1/5 1/5
2026-05-28 B- 2/5 1/5 5/5 5/5 1/5 1/5 1/5
2026-05-27 B- 2/5 1/5 5/5 5/5 1/5 1/5 1/5
2026-05-26 B- 2/5 1/5 5/5 5/5 1/5 1/5 1/5
2026-05-22 B- 2/5 1/5 5/5 5/5 1/5 1/5 1/5
2026-05-21 B- 2/5 1/5 5/5 5/5 1/5 1/5 1/5
2026-05-20 B- 2/5 1/5 5/5 5/5 1/5 1/5 1/5
2026-05-19 B- 2/5 1/5 5/5 5/5 1/5 1/5 1/5
2026-05-18 B- 2/5 1/5 5/5 5/5 1/5 1/5 1/5
2026-05-15 B- 3/5 1/5 5/5 5/5 1/5 2/5 1/5
2026-05-14 B- 3/5 1/5 5/5 5/5 1/5 2/5 1/5
2026-05-13 B- 3/5 1/5 5/5 5/5 1/5 2/5 1/5
2026-05-12 B- 3/5 1/5 5/5 5/5 1/5 2/5 1/5
2026-05-11 B- 3/5 1/5 5/5 5/5 1/5 2/5 1/5
2026-05-08 B- 3/5 1/5 5/5 5/5 1/5 2/5 1/5
2026-05-07 B- 3/5 1/5 5/5 5/5 1/5 2/5 1/5
2026-05-06 B- 3/5 1/5 5/5 5/5 1/5 2/5 1/5
2026-05-05 B- 3/5 1/5 5/5 5/5 1/5 2/5 1/5
2026-05-04 B- 3/5 1/5 5/5 5/5 1/5 2/5 1/5
2026-04-30 B- 3/5 1/5 5/5 5/5 1/5 2/5 1/5
2026-04-29 B- 3/5 1/5 5/5 5/5 1/5 2/5 1/5
2026-04-28 B- 3/5 1/5 5/5 5/5 1/5 2/5 1/5
2026-04-27 B- 3/5 1/5 5/5 5/5 1/5 2/5 1/5
2026-04-24 B- 3/5 1/5 5/5 5/5 1/5 2/5 1/5
2026-04-23 B- 3/5 1/5 5/5 5/5 1/5 2/5 1/5
2026-04-22 B- 3/5 1/5 5/5 5/5 1/5 2/5 1/5
2026-04-21 B- 2/5 1/5 4/5 5/5 1/5 2/5 1/5
2026-04-20 B- 2/5 1/5 4/5 5/5 1/5 2/5 1/5
2026-04-17 B- 3/5 1/5 4/5 5/5 1/5 2/5 2/5
2026-04-16 B- 3/5 1/5 4/5 5/5 1/5 2/5 2/5

Owner Earnings

Owner's Earnings (history) From To
Owner alignment
Owner's Earnings TTM
5.54B
OE per share TTM
3.20
Owner's Yield
72.05%
Maintenance CapEx ratio
743.96%
Maint CapEx / Avg PPE
416.0%

Ownership Overview

Ownership breakdown

Ownership breakdown not available.

At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)

No beneficial ownership filings recorded.

Institutional Activity (13F)

Institutional ownership trend

Institutional history not available.

Top institutional holders

Top holders not available.

ETF Ownership

Top ETFs holding this stock Held by 41 ETFs in our universe
# ETF Weight Est. AUM exposure TER
1 iShares MSCI China Small-Cap ETF ECNS 0.31% 201.4K 0.59%
2 Global X - Aging Population ETF AGNG 0.23% 194.0K 0.50%
3 WisdomTree China ex-State-Owned Enterprises Fund CXSE 0.08% 398.8K 0.32%
4 iShares Healthcare Innovation UCITS ETF HEAL.L 0.06% 731.7K 0.40%
5 iShares Ageing Population UCITS ETF AGED.L 0.05% 435.8K 0.40%
6 Avantis Emerging Markets Small Cap Equity ETF AVEE 0.05% 57.1K 0.42%
7 iShares MSCI AC Far East ex-Japan Small Cap UCITS ETF ISFE.L 0.05% 33.4K 0.74%
8 iShares MSCI Emerging Markets Small-Cap ETF EEMS 0.04% 132.6K 0.72%
9 iShares MSCI EM Small Cap UCITS ETF IEMS.L 0.03% 102.0K 0.74%
10 State Street SPDR MSCI Emerging Markets Small Cap UCITS ETF EMSD.L 0.03% 166.6K 0.55%

Insider Activity

Insider Activity — Latest Quarter

No insider activity available.

Insider buys vs sells (history)

Insider history not available.

Recent insider transactions

No recent insider transactions.

Executive team

Top executives
EBIT / Employee
175.6K
Shares Outstanding
1.80B

Executive compensation

Executive compensation (annual)

Executive compensation not available.

CEO compensation breakdown

No CEO compensation history available.

Proxy statements

Proxy statements (DEF 14A)

No proxy statements available for this company yet.

Recent SEC filings

Recent SEC filings

No SEC filings available for this company yet.

Executive team

NameTitleCompensationGender
Ziye Sui GM, CEO & Executive Director 4M —
Lixuan Zhao Employee Representative Supervisor & Investor Relations Director — female
Siu Kuen Lai FCIS Joint Company Secretary — female
Yunyi Li CFO & Joint Company Secretary — female
Zhongjie Pu Executive Chairman — —
ESG Score History

No data available for this company.

Senate Trading Activity

No Senate trading activity found for this company.

House Trading Activity

No House trading activity found for this company.

Market share among peers
Peer comparison — filtered group (TTM)
Your opinion

Share your view on this stock and instantly see how the community has voted over the last 6 months.

These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.

Dividend history

Earnings history

Earnings reports

Stock splits

Related companies

Largest companies in Biotechnology